ReviewFEMS microbiology reviews2026
Getting a grip on StAR-related lipid-transfer (START) domain proteins in bacteria.
Review in FEMS microbiology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
StAR-related lipid transfer (START) domain proteins comprise a conserved superfamily defined by a characteristic helix-grip fold that enables the binding of hydrophobic ligands. In mammals, START domain proteins have been extensively characterized as key mediators of nonvesicular lipid transport and lipid-dependent signalling pathways. In contrast, the prevalence, structural diversity, and functional roles of START domain proteins in bacteria remain underexplored and for those that are characterized, experimental findings are occasionally conflicting. While bacterial START domains preserve the core helix-grip fold for lipid binding, they are typically smaller and exhibit more limited conformational flexibility than their eukaryotic counterparts. Despite these apparent constraints, available experimental data suggest that bacterial START domains participate in a remarkably broad range of biological processes-including small-molecule binding, metabolic regulation, enzymatic catalysis, and stress adaptation-rather than traditional lipid transport. Bacteria within the phylum Actinomycetota, in particular, have evolved a prolific repertoire of START-domain proteins. As an example, we will discuss the START domain proteins of Mycobacterium tuberculosis in detail, one of which has emerged as a promising drug target. Collectively, this synthesis underscores the functional versatility of the START domain across the domains of life and identifies critical knowledge gaps that warrant further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.